ABSORPTION KINETICS OF ORAL SOTALOL COMBINED WITH CISAPRIDE AND SUBLINGUAL SOTALOL IN HEALTHY-SUBJECTS

Aims To study the absorption kinetics of sotalol following administrat ion of different formulations. A formulation which results in fast abs orption might be useful in the episodic treatment of paroxysmal suprav entricular tachycardia (SVT), atrial fibrillation (Afib) or atrial flu tter (Afl). Methods In an open randomized crossover study seven health y male volunteers were given an intravenous infusion of 20 mg sotalol, for assessing the absolute bioavailability, an oral solution containi ng 80 mg sotalol, an oral solution containing both 80 mg sotalol and 2 0 mg cisapride and an 80 mg sotalol tablet, which was taken sublingual ly. Results The addition of cisapride decreased the time at which maxi mum serum concentrations were reached (t(max)) from 2.79 (1.85-4.34) h to 1.16 (0.68-2.30) h (P=0.009) [95% CI: -2.59, -0.55] and increased the absorption rate constant (k(a)) from 0.49 (0.31-0.69) h(-1) to 1.2 6 (0.52-5.61) h(-1) (P=0.017). The absolute bioavailability of sotalol was reduced by cisapride from 1.00 +/- 0.15 to 0.70 +/- 0.26 (P=0.006 ), while maximum serum concentrations of both oral solutions were not significantly different. Compared with the sublingually administered t ablet with a median t(max) of 2.12 (0.89-3.28) h, the sotalol/cisaprid e oral solution gave a smaller t(max) (p=0.009) [95% CI: -1.64, -0.36] . The k(a) of the sotalol/cisapride solution was significanty (P=0.010 ) larger than the k(a) of 0.56 (0.33-0.75) h(-1) found after sublingua l administration of the tablet. Conclusions The sotalol/cisapride oral solution might be suitable for the episodic treatment of SVT, Afib or Afl.